Tyvyt

Innovent Biologics is a leading biopharmaceutical company headquartered in Suzhou, China, dedicated to developing and commercializing high-quality innovative medicines. The company's flagship product is Tyvyt (sintilimab), a PD-1 inhibitor co-developed with Eli Lilly that has achieved significant commercial success in the Chinese market across multiple oncology indications. Beyond its core immunotherapy portfolio, Innovent has successfully launched several biosimilars and is advancing a diverse pipeline of over 30 assets in oncology, metabolic, autoimmune, and ophthalmology therapeutic areas. The company's capabilities span the entire drug development lifecycle, including a robust R&D engine, large-scale GMP-compliant manufacturing, and an extensive commercial infrastructure. Strategic collaborations with global pharmaceutical leaders like Roche, Sanofi, and Incyte further validate its platform and expand its global reach.